An interventional study of Combined Aerobic and Resistance Exercise and Combined Aerobic and Resistance Exercise in Hemodialysis, sponsored by Ibadat International University, Islamabad. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Ibadat International University, Islamabad · Not applicable, Interventional, and Treatment
The purpose of this randomized controlled trial is to determine the optimal exercise duration of a combined exercise program (aerobic + resistance) in patients undergoing hemodialysis by evaluating its effects on dialysis adequacy, fatigue, depression, VO2 max, muscle strength, physical functioning, and QOL in patients undergoing hemodialysis.
1,860 studies on the registry are indexed under Fatigue; 376 are open to participants now.
This study's planned enrollment of 120 is above the median of 54 across 1,440 interventional studies indexed under Fatigue.
Browse Fatigue studies →Ibadat International University, Islamabad is the lead sponsor of 49 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
30-Minute Combined Aerobic and Resistance Exercise Participants in this group will receive a structured 30-minute combined aerobic and resistance exercise program
Other: Combined Aerobic and Resistance Exercise
40-Minute Combined Aerobic and Resistance Exercise Participants in this group will receive a structured 40-minute combined aerobic and resistance exercise program.
Other: Combined Aerobic and Resistance Exercise
Group C - 50-Minute Combined Aerobic and Resistance Exercise Participants in this group will receive a structured 50-minute combined aerobic and resistance exercise program.
Other: Combined Aerobic and Resistance Exercise
Arm 1: Group A - 30-Minute Exercise Intervention Participants will receive a 30-minute combined aerobic and resistance exercise program. Each session will include 5 minutes of warm-up (active ROM and deep breathing), 10 minutes of moderate-intensity stationary cycling (RPE 11-13), 10 minutes of resistance exercise at approximately 60% 1-RM, and 5 minutes of cool-down. Resistance exercises will include upper- and lower-limb exercises using weight cuffs. Participants will perform 1 set of 10 repetitions per exercise, with 10-15 seconds of rest between exercises. Resistance will be progressed weekly according to 1-RM.
Arm 2: Group B - 40-Minute Exercise Intervention Participants will receive a 40-minute combined aerobic and resistance exercise program. Each session will include 5 minutes of warm-up, 15 minutes of moderate-intensity stationary cycling (RPE 11-13), 15 minutes of resistance exercise at approximately 60% 1-RM, and 5 minutes of cool-down. Participants will perform 1 set of 15 repetitions per resistance exercise, with 10-15 seconds of rest between exercises. Resistance will be progressed weekly according to 1-RM.
Arm 3: Group C - 50-Minute Exercise Intervention Participants will receive a 50-minute combined aerobic and resistance exercise program. Each session will include 5 minutes of warm-up, 20 minutes of moderate-intensity stationary cycling (RPE 11-13), 20 minutes of resistance exercise at approximately 60% 1-RM, and 5 minutes of cool-down. Participants will perform 2 sets of 10 repetitions per resistance exercise, with 10-15 seconds of rest between exercises. Resistance will be progressed weekly according to 1-RM.
Dialysis adequacy
Dialysis adequacy will be assessed using the Kt/V value obtained through direct measurement from the dialyzer. Kt/V is a measure of urea clearance during hemodialysis and will be used to evaluate the adequacy of dialysis treatment.
Time frame: Baseline, Week 6, and Week 12.
Muscle Strength
Muscle strength will be assessed using an electronic hand dynamometer. Grip strength will be measured according to a standardized testing procedure.
Time frame: Baseline, Week 6, and Week 12
Physical Functioning
Physical functioning will be assessed using the 6-Minute Walk Test. Participants will be instructed to walk for 6 minutes at their own maximal sustainable pace, and the total distance walked in meters will be recorded. Greater walking distance will indicate better functional exercise capacity.
Time frame: Baseline, Week 6, and Week 12
VO₂ Max
VO₂ max will be assessed using the 6-minute walk test. Participants will walk for 6 minutes on a 30-meter flat surface, and the total distance covered in six minutes will be recorded in meters. Heart rate and systolic blood pressure will be measured before and immediately after the test. Estimated peak oxygen uptake will be calculated using the validated Cahalin prediction equation.
Time frame: Baseline, Week 6, and Week 12
Fatigue
Fatigue will be assessed objectively during the 6-Minute Walk Test (6MWT) by comparing the distance walked during the first and sixth minutes. The Walking Distance Index (DWI) will be calculated as DWI = \[(distance walked during the sixth minute - distance walked during the first minute) / distance walked during the first minute\] × 100. More negative DWI values indicate greater decline in walking performance during the test and therefore greater walking-related performance fatigability.
Time frame: Baseline, Week 6, and Week 12
Depression
Depressive symptoms will be assessed using the validated Urdu version of the Depression Anxiety Stress Scale-21 (DASS-21 Urdu). The depression subscale will be used to quantify the severity of depressive symptoms, with higher scores indicating greater symptom severity.
Time frame: Baseline, Week 6, and Week 12.
Health-related quality of life
Quality of life will be assessed using the Kidney Disease Quality of Life-36 questionnaire. The instrument assesses kidney disease-specific quality of life and the impact of kidney disease and its treatment on participants' physical and mental well-being. Scores will be calculated according to the instrument's scoring procedure, with higher scores indicating better health-related quality of life.
Time frame: Baseline, Week 6, and Week 12.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ibadat International University, Islamabad